A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.
Bilgrami
S
S
Bone Marrow Transplant Program, University of Connecticut Health Center, Farmington, Conn 06030, USA.
Edwards
R L
RL
Bona
R D
RD
Kazierad
D
D
Furlong
F
F
Fox
J
J
Clive
J
J
Naqvi
B H
BH
Tutschka
P J
PJ
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012008:Recurrence; D012074:Remission Induction; D014182:Transplantation, Autologous
D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan